SUPPLEMENTARY MATERIAL

Admission blood glucose is an independent risk factor of poor prognosis in COVID-19 patients: A systematic review and dose-response meta-analysis

Gilbert Lazarus¹, Jessica Audrey¹, Vincent Kharisma Wangsaputra¹, Alice Tamara¹, Dicky Levenus Tahapary^{2,3}

¹Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia

²Division of Endocrinology and Metabolism, Department of Internal Medicine,

Dr. Cipto Mangunkusumo General Hospital, Faculty of Medicine Universitas Indonesia,

Central Jakarta, Jakarta, Indonesia

³Metabolic, Cardiovascular and Aging Cluster, The Indonesian Medical Education and Research Institute, Faculty of Medicine Universitas Indonesia, Central Jakarta, Jakarta, Indonesia

Supplementary Material	Page
Methods	<u>3</u>
Search strategy	<u>3</u>
Table S1. Search strategies	<u>3</u>
Study eligibility criteria	<u>6</u>
Table S2. PICOTS framework	<u>6</u>
Data extraction and risk of bias assessment	<u>7</u>
Table S3. QUIPS tool signaling question	<u>8</u>
Statistical analysis	<u>11</u>
Results	<u>14</u>
Table S4. Characteristics of included studies	<u>14</u>
Figure S1. Risk of bias summary for included studies as assessed with the Quality in	<u>17</u>
Prognostic Studies tool	
Table S5. Pooled unadjusted estimates of high vs low meta-analysis on the association	<u>18</u>
between admission blood glucose and outcomes of COVID-19 patients	
Table S6. Summary of certainty of evidence as assessed with the GRADE approach	<u>19</u>

Table and Contents

Table S7. Locations of included studies originating from China	<u>23</u>
Figure S2. Leave-one-out sensitivity analysis of high vs low meta-analysis between	<u>25</u>
admission fasting blood glucose and outcomes on (A) poor outcome, (B) mortality and (C)	
severity	
Figure S3. Contour-enhanced funnel plot with pseudo 95% confidence interval indicating	<u>26</u>
evidence of publication bias (as shown by asymmetry) for high vs low meta-analysis	
evaluating admission fasting blood glucose level and mortality in COVID-19 patients	
Figure S4. Linear dose-response relationship between admission FBG level and mortality	<u>26</u>
in non-diabetic COVID-19 patients	
Table S8. Outcomes on the association of admission fasting blood glucose and prognosis	<u>27</u>
of COVID-19 patients	
Table S9. Sensitivity analysis for linear dose-response meta-analysis on the association	<u>33</u>
between admission fasting blood glucose concentration and mortality and severity in	
COVID-19 patients	
Figure S5. Sensitivity analysis for non-linear dose-response meta-analysis of severity	<u>34</u>
outcome according to location of knots	
Table S10. Outcomes on the association of admission random blood glucose and prognosis	<u>35</u>
of COVID-19 patients	
Supplementary References	<u>38</u>

SUPPLEMENTARY METHODS

Search strategy

We initially searched PubMed, EMBASE (via Ovid), Cochrane Controlled Register of Trials (CENTRAL), MEDLINE (via EBSCO), Cumulative Index to Nursing and Allied Health Literature (CINAHL), and Scopus databases for studies published up to 8 September 2020 using keywords listed on Table S1. Then, we additionally searched grey literature (viz, Google Scholar and ProQuest), preprint (via, MedRxiv and BioRxiv), and the World Health Organization (WHO) COVID-19 research databases, in addition to manually hand-searching reference lists from included studies and similar reviews. Lastly, we collected the PubMed ID of each included studies and ran additional search using the PubMed's 'similar articles' algorithm. Subsequently, the retrieved results were deduplicated and screened against the prespecified eligibility criteria.

Database	Keywords
PubMed	((("blood glucose"[MeSH Terms]) AND (("fasting"[MeSH Terms]) OR
	("postprandial period"[MeSH Terms]))) OR ("glucose tolerance
	test"[MeSH Terms]) OR "fasting blood glucose" OR "fasting plasma
	glucose" OR "fasting blood sugar" OR "fasting plasma sugar" OR
	"admission blood glucose" OR "admission plasma glucose" OR
	"admission blood sugar" OR "admission plasma sugar" OR "initial plasma
	glucose" OR "initial blood glucose" OR "initial blood sugar" OR "initial
	plasma sugar" OR "post-load blood glucose" OR "post-load plasma
	glucose" OR "post-load blood sugar" OR "post-load plasma sugar" OR
	"postprandial blood glucose" OR "postprandial plasma glucose" OR
	"postprandial blood sugar" OR "postprandial plasma glucose" OR
	"postprandial glucose" OR "postprandial glucose excursions" OR "oral
	glucose tolerance" OR "2 hours plasma glucose" OR "2 hours blood
	glucose" OR "2 hours blood sugar" OR "2 hours plasma sugar") AND
	("novel coronavirus" OR ("Coronavirus"[MeSH Terms]) OR
	("Coronavirus Infections"[MeSH Terms]) OR "coron?virus*" OR
	"coron?virinae*" OR "coronavirus" OR "2019-nCoV" OR "nCoV-2019"
	OR "COVID-19" OR "HCoV-19" OR "N-cov" OR "SARS-CoV-2" OR
	"SARS-Cov-19" OR "2019-new coronavirus" OR "2019-ncov" OR
	"2019?novel coronavirus" OR "Ncorona*" OR "COVID19" OR
	"HCoV19" OR "Ncov" OR "SARSCoV2" OR "SARSCoV19" OR
	"2019novel-coronavirus" OR "2019ncov" OR "2019new-coronavirus"))
PubMed's	16759303[PMID] OR 32406594[PMID] OR 32503812[PMID] OR
'similar	32602202[PMID] OR 32446795[PMID] OR 32638507[PMID] OR
articles'-	32647915[PMID] OR 32712122[PMID] OR 32409504[PMID] OR
algorithm	32167524[PMID] OR 32754119[PMID] OR 32469464[PMID] OR

Table	S1 .	Search	strategies
-------	-------------	--------	------------

	32472191[PMID] OR 32430456[PMID] OR 32788285[PMID] OR
	32842719[PMID] OR 32853687[PMID] OR 32357072[PMID] OR
	32636061[PMID] OR 32805345[PMID] OR 32389027[PMID] OR
	32360710[PMID] OR 32384078[PMID] OR 32623030[PMID] OR
	32758659[PMID]
Ovid	(blood glugges mp. or glugges blood level) and (fasting mp. or fasting/or
	((blood glucose.inp. of glucose blood level/) and (fasting.inp. of fasting/ of
EMDASE	postprandial state/ or postprandial.mp.)) or (lasting blood glucose or
	fasting plasma sugar or admission blood glucose or admission plasma
	glucose or admission blood sugar or admission plasma sugar or initial
	plasma glucose or initial blood glucose or initial blood sugar or initial
	plasma sugar or post-load blood glucose or postprandial blood sugar or
	postprandial plasma glucose or postprandial glucose or postprandial
	glucose excursions or oral glucose tolerance or 2 hours plasma glucose or
	2 hours blood glucose or 2 hours blood sugar or 2 hours plasma
	sugar).mp.)) and ((coronavirus infection.mp. or Coronavirus infection/ or
	SARS coronavirus/ or Coronavirus/) or (coron?virus* or coron?virinae* or
	coronavirus or 2019-ncov or ncov-2019 or covid-19 or hcov-19 or n-cov
	or sars-cov-2 or sars-cov-19 or 2019-new coronavirus or 2019-ncov or
	2019?novelcoronavirus or ncorona* or covid19 or hcov19 or ncov or
	sarscov2 or sarscov19 or 2019novel-coronavirus or 2019ncov or 2019new-
	coronavirus or sars coronavirus or coronavirus).mp.))
CENTRAL	#1 MeSH descriptor: [Coronavirus] explode all trees
	#2 MeSH descriptor: [Coronavirus Infections] explode all trees
	#3 MeSH descriptor: [Blood Glucose] explode all trees
	#4 MeSH descriptor: [Fasting] explode all trees
	#5 MeSH descriptor: [Patient Admission] explode all trees
	#6 MeSH descriptor: [Postprandial Period] explode all trees
	#7 MeSH descriptor: [Glucose Tolerance Test] explode all trees
	#8 (#3 OR #7) AND #5 AND {OR #4-#6}
	#9 {OR #1-#2} OR "coron?virus*" OR "coron?virinae*" OR "corona-
	virus" OR "2019-nCoV" OR "nCoV-2019" OR "COVID-19" OR
	"HCoV-19" OR "N-cov" OR "SARS-CoV-2" OR "SARS-Cov-19"
	OR "2019-new coronavirus" OR "2019-ncov" OR "2019?novel
	coronavirus" OR "Ncorona*" OR "COVID19" OR "HCoV19" OR
	"Ncov" OR "SARSCoV2" OR "SARSCoV19" OR "2019novel-
	coronavirus" OR "2019ncov" OR "2019new-coronavirus"
	#10 #8 OR "fasting blood glucose" OR "fasting plasma glucose" OR
	"fasting blood sugar" OR "fasting plasma sugar" OR "admission blood
	glucose" OR "admission plasma glucose" OR "admission blood sugar"
	OR "admission plasma sugar" OR "initial plasma glucose" OR "initial
	blood glucose" OR "initial blood sugar" OR "initial plasma sugar" OR
	"post-load blood glucose" OR "post-load plasma glucose" OR "post-
	load blood sugar" OR "post-load plasma sugar" OR "postprandial
	blood glucose" OR "postprandial plasma glucose" OR "postprandial
	blood sugar" OR "postprandial plasma glucose" OR "postprandial
	glucose" OR "postprandial glucose excursions" OR "oral glucose
	tolerance" OR "2 hours plasma glucose" OR "2 hours blood glucose"
	OR "2 hours blood sugar" OR "2 hours plasma sugar"
	#11 #9 AND #10

ProOuest	((MESH("patient admission" AND ("fasting" OR "postprandial period")
(AND ("blood glucose" OR "glucose tolerance test")) OR "fasting blood
	glucose" OR "fasting plasma glucose" OR "fasting blood sugar" OR
	"fasting plasma sugar" OR "admission blood glucose" OR "admission
	plasma glucose" OR "admission blood sugar" OR "admission plasma
	sugar" OR "initial plasma glucose" OR "initial blood glucose" OR "initial
	blood sugar" OR "initial plasma sugar" OR "post-load blood glucose" OR
	"post-load plasma glucose" OR "post-load blood sugar" OR "post-load
	plasma sugar" OR "postprandial blood glucose" OR "postprandial plasma
	glucose" OR "postprandial blood sugar" OR "postprandial plasma glucose"
	OR "postprandial glucose" OR "postprandial glucose excursions" OR "oral
	glucose tolerance" OR "2 hours plasma glucose" OR "2 hours blood
	glucose" OR "2 hours blood sugar" OR "2 hours plasma sugar") AND
	(MESH("Coronavirus" OR "Coronavirus infections") OR "coron?virus*"
	OR "coron?virinae*" OR "corona-virus" OR "2019-nCoV" OR "nCoV-
	2019" OR "COVID-19" OR "HCoV-19" OR "N-cov" OR "SARS-CoV-2"
	OR "SARS-Cov-19" OR "2019-new coronavirus" OR "2019-ncov" OR
	"2019?novel coronavirus" OR "Ncorona*" OR "COVID19" OR
	"HCoV19" OR "Ncov" OR "SARSCoV2" OR "SARSCoV19" OR
	"2019novel-coronavirus" OR "2019ncov" OR "2019new-coronavirus"))
Google	(((("initial" OR "admission") AND ("fasting" OR "postprandial")) OR
Scholar	("blood glucose" OR "blood sugar" OR "plasma glucose" OR "plasma
	sugar")) AND ("COVID-19" OR "SARS-CoV-2" OR "2019-ncov" OR
	"novel coronavirus"))
CINAHL,	S1 (MH "Blood Glucose")
MEDLINE	S2 (MH "Patient Admission") OR (MH "Fasting")
(via EBSCO)	S3 S1 AND S2
	S4 S3 OR ("fasting blood glucose" OR "fasting plasma glucose" OR
	"fasting blood sugar" OR "fasting plasma sugar" OR "admission blood
	glucose" OR "admission plasma glucose" OR "admission blood sugar"
	OR "admission plasma sugar" OR "initial plasma glucose" OR "initial
	blood glucose" OR "initial blood sugar" OR "initial plasma sugar" OR
	"post-load blood glucose" OR "post-load plasma glucose" OR "post-
	load blood sugar" OR "post-load plasma sugar" OR "postprandial
	blood glucose" OR "postprandial plasma glucose" OR "postprandial
	blood sugar" OR "postprandial plasma glucose" OR "postprandial
	glucose" OR "postprandial glucose excursions" OR "oral glucose
	tolerance" OR "2 hours plasma glucose" OR "2 hours blood glucose"
	OR "2 hours blood sugar" OR "2 hours plasma sugar)
	S5 ((MH "Coronavirus Infections+") OR (MH "COVID-19") OR
	"coron?virus*" OR "coron?virinae*" OR "corona-virus" OR "2019-
	nCoV" OK "nCoV-2019" OK "COVID-19" OK "HCoV-19" OR "N-
	cov" OK "SARS-CoV-2" OR "SARS-Cov-19" OR "2019-new-
	coronavirus" OR "2019-ncov" OR "2019-novel-coronavirus" OR
	INCORONA [®] UK "UUVID19" UK "HCoV19" UK "NCOV" UK
	SAKSUOVZ UK SAKSUOVI9 UK 2019novel-coronavirus UK
	2019ncov [®] UK [®] 2019new-coronavirus [®]))
Saanna	50 54 AIND 55 ((TITLE ADS VEV("footing blood glugges" OD "footing glooms glugges")
Scopus	(111 LE-ABS-KET (lasting blood glucose" OK "lasting plasma glucose" OB "footing blood sugar" OB "footing plasma guager" OB "admission blood
	OK Tashing Dioou sugar OK Tashing piasina sugar OK adhiission blood

Bratost of admission prasma Bratoste of admission brood sugar off
"admission plasma sugar" OR "initial plasma glucose" OR "initial blood
glucose" OR "initial blood sugar" OR "initial plasma sugar" OR "post-load
blood glucose" OR "post-load plasma glucose" OR "post-load blood sugar"
OR "post-load plasma sugar" OR "postprandial blood glucose" OR
"postprandial plasma glucose" OR "postprandial blood sugar" OR
"postprandial plasma glucose" OR "postprandial glucose" OR
"postprandial glucose excursions" OR "oral glucose tolerance" OR "2
hours plasma glucose" OR "2 hours blood glucose" OR "2 hours blood
sugar" OR "2 hours plasma sugar")) AND (TITLE-ABS-
KEY("coron?virus*" OR "coron?virinae*" OR "corona-virus" OR "2019-
nCoV" OR "nCoV-2019" OR "COVID-19" OR "HCoV-19" OR "N-cov"
OR "SARS-CoV-2" OR "SARS-Cov-19" OR "2019-new-coronavirus" OR
"2019-ncov" OR "2019-novel-coronavirus" OR "Ncorona*" OR
"COVID19" OR "HCoV19" OR "Ncov" OR "SARSCoV2" OR
"SARSCoV19" OR "2019novel-coronavirus" OR "2019ncov" OR
"2019new-coronavirus")))
MedRxiv, (((("postprandial" OR "fasting" OR "random") AND "glucose")) AND
BioRxiv ("COVID-19" OR "SARS-CoV-2))
WHO ((tw:(("fasting" OR "postprandial" OR "random") AND ("glucose" OR
COVID-19 "sugar"))))
Research
Database

CENTRAL, Cochrane Controlled Register of Trials; **CINAHL**, Cumulative Index to Nursing and Allied Health Literature. **WHO**, World Health Organization.

Study eligibility criteria

In accordance to the objectives of our meta-analysis, we developed a 'Population, Index prognostic factor, Comparator prognostic factor, Outcome, Timing, Settings' (PICOTS) framework adapted from the guideline proposed by Riley et al¹.

Item	Definition
Population	Patients with COVID-19 infection
Index prognostic factor	Blood glucose concentration (i.e. FBG and RBG)
Comparator prognostic	None
factor	
Outcome	Death or progression to severe COVID-19 cases-further
	investigated per criterion: ARDS, shock, patients requiring
	ICU admission, and patients requiring invasive ventilation
Timing	Prognostic factor: at admission

 Table S2. PICOTS framework

	Outcome: at any point
Setting	To provide prognostic information about COVID-19
	patients; this information may help clinicians in stratifying
	the risk among COVID-19 patients

ARDS, acute respiratory distress syndrome; COVID-19, coronavirus disease 2019; FBG, fasting blood glucose; **PICOTS**, population, index prognostic factor, comparator, outcome, timing, and setting; **RBG**, random blood glucose.

Data extraction and risk of bias assessment

The following essential data were extracted: (1) author and year of publication; (2) study characteristics, viz. recruitment period, study design, location, and sample size; (3) patient characteristics, viz. age in years, proportion of male populations, comorbidities, blood glucose (BG) marker, and admission BG level; and (4) outcomes and its effect sizes. In the case of unidentifiable blood glucose marker, corresponding authors were contacted to obtain the missing data, and the articles were subsequently excluded when no response was provided by the authors.

During extraction, admission BG level of any cut-off value and any effect size (both adjusted and unadjusted) were incorporated. In the case where studies only reporting time-toevent outcomes using the Kaplan-Meier curve, data were digitized with GetData Graph Digitizer ver. 2.26 (www.getdata-graph-digitizer.com) and hazard ratios (HRs) were estimated using the formula proposed by Tierney et al². Similarly, the unadjusted relative risk (RR) was also calculated from binary data using the provided formula³, whenever available. The included studies were further investigated for risk of bias using a tailored version of the Quality in Prognosis Studies (QUIPS) tool⁴, which assessed the study-specific risk of bias across to six bias domains: study participation, study attrition, prognostic factor measurement, outcome measurement, and study confounding, and statistical analysis and reporting. Details on each signaling question of the QUIPS tool are elaborated on Table S3.

Signaling question	Issues to consider for author's judgment of 'yes'
1. Study participation: yes	/no/unclear/NA ^a
a. Description of source of population or population of interest	Source population for cohort with COVID-19 is clearly described

b. Adequate description of sampling frame and recruitment	Methods of sampling and limiting potential bias arising from participant selection are described (i.e. no selective sampling)	
c. Adequate description of recruitment period	Period of recruitment is clearly described	
d. Adequate description of place of recruitment	Place of recruitment is clearly described	
e. Adequate description of inclusion and exclusion criteria	Definition of patients with COVID-19 and other inclusion and exclusion criteria are described	
f. Adequate participation in the study by eligible individuals	Proportion of COVID-19 patients participating in the study is adequate	
g. Description of baseline study sample	Baseline characteristics of COVID-19 patients are clearly described	
Study participation: risk of bias	High : Most items are answered with 'no'; Low : Most items are answered with 'yes'; Unclear : Most items are answered with 'unclear'	
	Note: A single 'no' answer may potentially result in high risk of bias, depending on study specifics	
2. Study attrition: yes/no/u	inclear	
a. Adequate response rate for study participants	Proportion of COVID-19 patients completing the study with outcome data is adequate (<10% missing)	
b. Description of attempts to collect information on participants who dropped out	Attempts to collect information on participants who dropped out are clearly described	
c. Reasons for loss to follow-up provided	Reasons of participants who dropped out are provided (e.g. transferred to another hospital)	
d. Adequate description of participants lost to follow up	Key characteristics of participants who dropped out are described (e.g. age, sex, admission blood glucose)	
e. No important differences between participants who completed the study and those who did not	Differences between participants completing the study and those who did not are described as not important, or information to judge the differences, if any, are provided	
Study attrition: risk of bias	High : Most items are answered with 'no'; Low : Most items are answered with 'yes'; Unclear : Most items are answered with 'unclear'	
	Note: A single 'no' answer may potentially result in high risk of bias, depending on study specifics	
3. Blood glucose measurement: yes/no/unclear/NA ^a		
a. A clear definition or description of blood glucose measured is provided	Measurement for admission blood glucose are provided (e.g. FBG, RBG)	

b. Method of blood glucose measurement is adequately valid and	Method of obtaining admission blood glucose measurement is valid and reliable (e.g. laboratory measurements)
c. Continuous variables reported or appropriate cut points used	Standard categories or cut-off points to classify admission blood glucose are used
d. Method and setting of measurement of blood glucose is the same for all study participants	Measurement of admission blood glucose is the same for all study participants
e. Adequate proportion of the study sample has complete data for blood glucose variable	Proportion of study sample with complete admission blood glucose data available for analysis is adequate
f. Appropriate methods of imputation were used for missing data	NA: missing laboratory measurements for admission blood glucose cannot be reliably imputed
Blood glucose measurement: risk of bias	High : Most items are answered with 'no'; Low : Most items are answered with 'yes'; Unclear : Most items are answered with 'unclear'
	Note: A single 'no' answer may potentially result in high risk of bias, depending on study specifics
4. Outcome measurement:	yes/no/unclear
a. Clear definition of the outcome provided	Measurement of poor composite outcome, mortality, or severity criteria should be clearly defined
b. Method of outcome measurement used is adequately valid and reliable	Method of outcome ascertainment is valid and reliable: based on events reported on medical records (e.g. ICU admission, death) or valid severity criteria
c. Method and setting of outcome measurement is the same for all study participants	Measurement of poor composite outcome, severity, or mortality should be the same for all study participants
Outcome measurement: risk of bias	High : Most items are answered with 'no'; Low : Most items are answered with 'yes'; Unclear : Most items are answered with 'unclear'
	Note: A single 'no' answer may potentially result in high risk of bias, depending on study specifics
5. Study confounding: yes/	/no/unclear
a. Important confounders are measured	Important confounders are age, sex, and comorbidities
b. Clear definitions of the important confounders measured are provided	Definition and measurement of confounders are clearly described
c. Measurement of	Measurement of confounders is valid and reliable

adequately valid and reliable	
d. Same method and setting of confounding measurement in all study participants	Measurements of confounders are the same for all study participants
e. Appropriate methods are used if imputation is used for missing confounder data	Methods to impute missing confounder data, if any, are appropriate and clearly described
f. Important potential confounders are accounted for in the study design	Strategies to account for potential confounders are described in the methods section of the study
g. Important potential confounders are accounted for in the analysis	Important confounders are accounted for in multivariable logistic regression and Cox proportional hazards models
Study confounding: risk of bias	High : Most items are answered with 'no'; Low : Most items are answered with 'yes'; Unclear : Most items are answered with 'unclear'
	Note: A single 'no' answer may potentially result in high risk of bias, depending on study specifics
6. Statistical analysis and 1	reporting: yes/no/unclear/NA ^a
a. Sufficient presentation of data to assess the adequacy of the analysis	Mean or median values of variables are appropriately reported with standard deviations or interquartile range, results are properly reported with confidence intervals or standard errors
b. Strategy for model building is appropriate and based on a conceptual framework or model	NA: Since the research question focuses on only one prognostic factor, model building strategies or conceptual framework are not expected
c. The selected statistical model is adequate for the design of the study	Univariate and multivariate logistic regression or Cox proportional hazard model are used as appropriate
d. No selective reporting of results	NA: admission blood glucose as the prognostic factor of
	interest and its relation to severity or mortality should be reported, or else study would be excluded
Statistical analysis and reporting: risk of bias	 interest and its relation to severity or mortality should be reported, or else study would be excluded High: Most items are answered with 'no'; Low: Most items are answered with 'yes'; Unclear: Most items are answered with 'unclear' Note: A single 'no' answer may potentially result in high risk
Statistical analysis and reporting: risk of bias	 interest and its relation to severity or mortality should be reported, or else study would be excluded High: Most items are answered with 'no'; Low: Most items are answered with 'yes'; Unclear: Most items are answered with 'unclear' Note: A single 'no' answer may potentially result in high risk of bias, depending on study specifics

Moderate: All cases not fulfilling criteria for either low or high risk of bias

^aNA (not applicable): The signaling question is not applicable to this type of prognostic review. **COVID-19**, Coronavirus disease 2019; FBG, fasting blood glucose, **ICU**, intensive care unit; **NA**, not applicable; RBG, random blood glucose; **QUIPS**, Quality in Prognostic Studies tool

Statistical analysis

Data syntheses were performed to assess the association between admission BG level (i.e. fasting BG [FBG] and random BG [RBG]) and poor outcome in COVID-19 patients. We analyzed poor outcome (i.e. composite endpoint of mortality or severity), mortality, and severity separately to prevent any model selection bias, as some studies reported mortality and severity separately. When the studies utilized two-hours postprandial glucose level as the exposure, we assumed the value of 7.8 and 11.1 mmol/L to be equivalent to FBG level of 5.6 and 7.0 mmol/L, respectively.⁵

All outcomes were presented in relative risks (RRs). Odds ratios (ORs) were converted to RRs as per Cochrane recommendations⁶; while hazard ratios (HRs) by using the formula provided by VanderWeele et al when outcome probabilities of both exposed and non-exposed groups fell between 20% and 80%⁷. When the outcome probabilities of either group were relatively small, HR was used interchangeably with RR due to close approximates. This approach has been proven to yield smaller bias ratios than indifferent interchangeable use of HRs and RRs.⁷

Meta-analysis was first conducted by pooling the highest vs lowest category of exposures (i.e. admission BG level) using the DerSimonian-Laird random-effects model. We deemed that random-effects model was the most appropriate model due to the likeliness of unexplained heterogeneity in prognostic reviews.¹ Heterogeneity was classified as negligible, low, moderate, or high to I² values of 0%, 25%, 50%, and 75%, respectively⁸; while P value of <0.10 indicated statistical significance for Q statistics. In the case where two or more studies involved overlapping populations, analysis was prioritized to studies with larger sample sizes. Dependencies of study effects were screened according to the heuristic proposed by Wood et al, taking into account the following criteria: (1) study location, (2) recruitment period, and (3) overlapping co-authors.⁹

For the dose-response meta-analysis (DRMA), we first assigned the reported mean or median admission BG level of each category, or estimated the midpoint of lower and upper bounds of the respective category (when only range was reported) for each included study. The interval length of the highest open-ended category was assumed to be 1.5 times the width of the adjacent category; while the lower limit of the open-ended lowest category was estimated to be 3.9 mmol/L.¹⁰ Then, we estimated the study-specific linear trend by using the two-stage random-effects model with generalized least squares method as described by Greenland and Longnecker¹¹. The estimated trends were subsequently pooled with two-stage random-effects meta-analysis. Non-linear dose-response meta-analysis was only conducted for studies reporting at least three categories. Details on the investigation of non-linear trends have been fully discussed in the main text.

Subgroup analyses were performed only when there were at least two studies in each subgroup (or when the subgroups are more than two, subgroup analyses were carried out if there were a minimum of two studies in at least two subsets). Subgroups were divided to explore potential sources of heterogeneity according to study design (prospective vs retrospective), sample size (<200 vs \geq 200 patients), location (China vs non-China), risk of bias (low vs moderate/high), number of category (two categories, >2 categories, and continuous), effect size type (HR vs RR), while subgroup analysis to evaluate possible disparities in clinical was carried out by comparing estimates between diabetic and non-diabetic patients. Although HR is usually expected to approximate similarly to RR when the outcomes are relatively rare⁷, we were unable to convert the effect size to RR when either cohorts' outcome probability lie beyond the range (i.e. <20% or >80%). Hence, we decided to perform subset analysis according to effect size type (i.e. RR and HR) to evaluate the possibility of heterogeneity arising from interchangeable use of effect sizes. In the case of studies not stratifying analysis of admission BG level based on diabetic status, corresponding authors were contacted to obtain additional data.

There were at least ten contacts attempted to confirm study settings (i.e. to ascertain whether the blood glucose was obtained in fasting or non-fasting state), verify potential overlapping populations, and/or to obtain additional data for dose-response analysis and/or diabetes-stratified analysis. Seven authors responded to our queries, of which four^{12–15} confirmed their study settings and/or overlapping populations, and three^{16–18} provided additional data for analysis. Following authors' confirmations, we excluded one study (i.e. Berenguer et al¹³) as the author could not confirm whether the admission blood glucose was obtained in fasting or non-fasting condition. In addition, Li et al¹⁸ confirmed potential overlapping population with Wang et al¹⁹, Zhang et al²⁰, and Zhu et al²¹, thus analysis was prioritized to Wang et al¹⁹ due to larger sample size.

Sensitivity analysis of high vs low meta-analysis was conducted by excluding studies with high risk of bias and sequentially removing each study one by one, while sensitivity analyses of dose-response meta-analysis were conducted for both linear and non-linear trends. Sensitivity analysis of linear trend was conducted by using alternative approaches in assigning the admission BG level for open-ended categories^{10,22}, while sensitivity analysis for non-linear dose-response meta-analysis was conducting by using alternative combination of knots locations (i.e. 10th, 25th, 50th, 75th, and 90th percentiles).²³ Meta-analysis was conducted using R ver. 4.0.0 (R Foundation for Statistical Computing, Vienna, Austria)²⁴ with the additional *meta* (ver. 4.9-6)²⁵, *dosresmeta* (ver. 2.0.1)²⁶, and *rms* (ver. 6.0-1)²⁷ packages.

SUPPLEMENTARY RESULTS

Table S4. Characteristics of included studies^a

		Study characte	ristics]	Patient ch	aracteristic	s					Admissio	n glucose level	D:1
Author;	Recruitment			Sample		Male			Co-mo	rbidities;	n(%)			Marker	(m	mol/L)	of
Year	period	Design	Location	size	Age (years)	(%)	Diabetes	нт	Stroke	CVD	CKD	Cancer	CLD	War Ker	Good outcome	Poor outcome ^b	bias ^c
Bode B; 2020 ²⁸	1 Mar - 6 Apr 2020	Retrospective	USA	1122	DM: 65 (Range: 24- 95) Non-DM: 61 (18-101)	624 (55.61)	451 (40.2)	NR	NR	NR	NR	NR	NR	RBG	NR	NR	+
Cai Y; 2020 ²⁹	20 Jan - 20 Feb 2020	Retrospective	China	941	57 (Range: 18-98)	454 (48.2)	123 (13.1)	272 (28.9)	64 (6.8)	NR	44 (4.7)	28 (3)	35 (3.7)	FBG	NR	NR	?
Cariou B; 2020 ³⁰	10 Mar - 10 Apr 2020	Retrospective	France	1317	69.8±13.0	855 (64.9)	1317 (100)	1003 (77.2)	163 (12.9)	336 (26.9)	60 (7.2)	194 (15.1)	133 (10.4)	RBG	8.80 (6.70- 12.10)	10.30 (7.10- 14.53)***	?
Chang MC; 2020 ³¹	1 Feb - 10 Apr 2020	Retrospective	South Korea	106	67.6±15.3	54 (50.1)	42 (39.6)	59 (55.7)	6 (5.7)	12 (11.3)	17 (16)	9 (8.5)	7 (6.6)	FBG	7.7±3.6	10.9±4.3***	?
Coppelli A; 2020 ¹⁵	20 Mar - 30 Apr 2020	Retrospective	Italy	271	72 (58-82)	181 (66.8)	56 (20.7)	NR	NR	NR	NR	NR	NR	RBG	NR	NR	-
Deng M; 2020 ³²	Up to 13 Mar 2020	Retrospective	China	65	Severe: 32.5 (20.5-37.5) Moderate: 35 (29-37)	36 (55.4)	2 (3.1)	3 (4.6)	NR	0 (0)	NR	1 (1.5)	NR	FBG	5.15 (4.66- 5.63)	6.77 (5.86- 8.92)***	?
Fadini GP; 2020 ¹⁶	21 Feb - 20 Apr 2020	Retrospective	Italy	413	64.9±15.4	245 (59.3)	306 (74.09)	212 (51.3)	NR	72 (18.0)	30 (7.3)	66 (16.6)	29 (7.3)	FBG	NR	NR	-
Gao S; 2020 ³³	23 Jan - 29 Feb 2020	Retrospective	China	210	71 (67-77)	101 (48.1)	38 (18.1)	115 (54.8)	13 (6.2)	52 (24.8)	18 (8.6)	6 (2.9)	3 (1.4)	FBG	5.5 (4.7- 6.9)	6.9 (5.0-7.9)	-
Gupta R; 2020 ³⁴	Mar - Apr 2020	Retrospective	USA	496	70 (60-78)	260 (53.9)	276 (57.0)	406 (83.9)	NR	40 (8.1)	117 (23.6)	44 (9.1)	30 (6.7)	RBG	7.1 (5.8- 10.2)	10.1 (72- 15.3)***	?
Han M; 2020 ³⁵	2 Feb - 15 Feb 2020	Retrospective	China	306	60 (49-70)	174 (56.9)	129 (42.2)	119 (38.9)	11 (3.6)	25 (8.2)	4 (1.3)	3 (1)	18 (5.9)	FBG, RBG	NR	NR	-
Huang R; 2020 ³⁶	22 Jan – 10 Feb 2020	Retrospective	China	202	44 (33-54)	116 (57.4)	19 (9.4)	29 (14.4)	3 (1.5)	5 (2.5)	NR	2 (1)	7 (3.5)	FBG	5.7 (6.1- 6.6)	6.5 (5.5- 8.0)***	+
Iacobellis G; 2020 ³⁷	4 Mar - 4 Apr 2020	Retrospective	USA	85	65 (Range: 31-95)	49 (57.6)	27 (31.8)	NR	NR	NR	NR	NR	NR	RBG	NR	NR	+
Li H; 2020 ¹⁸	22 Jan - 17 Mar 2020	Retrospective	China	453	61 (49-68)	236 (52.1)	98 (21.6)	150 (33.1)	16 (3.5)	44 (9.7)	8 (1.8)	29 (6.4)	25 (5.5)	FBG	NR	NR	-
Li Y; 2020 ³⁸	31 Dec 2019 - 5 Apr 2020	Retrospective	China	132	65 (57-71)	70 (53.0)	132 (100)	85 (64.4)	12 (9.1)	NR	4 (3)	3 (2.3)	4 (3)	FBG	NR	NR	-
Liu SP; 2020 ³⁹	1 Feb - 24 Feb 2020	Retrospective	China	255	64 (24-92)	136 (53.3)	51 (20)	101 (39.6)	NR	28 (10.9)	NR	NR	8 (31.4)	FBG	5.8 (3.9– 18.9)	10.1 (4.8– 23.1)***	?
Long Q; 2020 ¹⁷	2 Jan - 15 Feb 2020	Retrospective	China	522	54.2 (43.3- 68.9)	250 (47.9)	94 (18.0)	130 (24.9)	NR	38 (7.2)	NR	NR	NR	FBG	6.32 (4.89- 6.70)	8.94 (5.93- 10.05)***	-
Marcos M; 2020 ¹²	15 Feb - 28 Apr 2020	Retrospective	Spain	918	72.8±14.5	531 (57.8)	213 (23.2)	489 (53.3)	91 (9.9)	104 (11.3)	50 (5.5)	130 (14.2)	115 (12.5)	RBG	7.2±3.2	8.4±3.9***	+

Mejía- Vilet JM; 2020 ⁴⁰	16 Mar - 21 May 2020	Prospective	Mexico	329	49 (41-60)	211 (64.1)	80 (24)	88 (27)	NR	NR	19 (6)	NR	NR	RBG	5.94 (5.38- 7.10)	7.66 (6.16- 11.82)***	-
Sardu C; 2020 ¹⁴	Since 20 Feb 2020	Retrospective	Italy	59	67.4 <u>±</u> 9.87	48 (81.4)	26 (44.1)	44 (74.6)	NR	12 (20.3)	NR	NR	NR	RBG	NR	NR	?
Shi Q; 2020 ⁴¹	1 Jan – 8 Mar 2020	Retrospective	China	306	64.5 (56-72)	150 (49)	153 (50)	131 (42.8)	14 (4.6)	49 (16)	12 (3.9)	14 (4.6)	21 (6.9)	FBG	DM: 8.5 (6.6- 12.1) Non-DM: 5.7 (4.8- 7.0)	DM: 12.7 (8.8-18.6)* Non-DM: 7.1 (5.1-12.2)	?
Smith SM; 2020 ⁴²	16 Mar - 2 May 2020	Prospective	USA	184	64.4 (Range: 21-100)	98 (53.3)	114 (62)	111 (60.3)	10 (5.4)	22 (12)	24 (13)	17 (9.2)	12 (6.5)	FBG	9.1	13.2*	+
Tu Y; 2020 ⁴³	10 Jan - 29 Feb 2020	Retrospective	China	75	68 (62-74)	53 (70.7)	14 (19)	30 (40)	5 (7)	13 (17)	1 (1.3)	NR	7 (9.3)	RBG	NR	NR	?
Wang F; 2020 ⁴⁴	29 Jan - 10 Feb 2020	Retrospective	China	28	68.6±9.0	21 (75)	28 (100)	15 (53.6)	4 (14.3)	4 (14.3)	0 (0)	NR	2 (14.3)	RBG	9.8±3.4	13.7±5.1*	+
Wang S; 2020 ¹⁹	24 Jan - 10 Feb 2020	Retrospective	China	605	59 (47-68)	322 (53.2)	0 (0)	139 (25.6)	16 (2.6)	NR	16 (2.6)	29 (4.8)	18 (3)	FBG	NR	NR	-
Wu C; 2020 ⁴⁵	25 Dec 2019 – 26 Jan 2020	Retrospective	China	201	51 (43-60)	128 (63.7)	22 (10.9)	39 (19.4)	NR	8 (4)	2 (1)	1 (0.5)	5 (2.5)	FBG	5.4 (4.9- 6.5)	7.4 (5.7- 10.08)***	?
Wu J; 2020 ⁴⁶	26 Dec 2019 - 15 Mar 2020	Retrospective	China	2387	Critical: 65 (54-73) Non-critical: 61 (50-69)	1200 (50.3)	332 (13.9)	662 (27.7)	NR	NR	58 (2.4)	34 (1.4)	85 (3.6)	FBG	5.9 (5.1- 7.5)	NR	-
Yan Y; 2020 ⁴⁷	10 Jan - 24 Feb 2020	Retrospective	China	192	64 (49-73)	114 (59.1)	48 (24.9)	73 (37.8)	8 (4.1)	31 (16.1)	4 (2.1)	NR	14 (7.3)	RBG	9.02 (6.39- 13.73)	12.38 (8.39- 17.35)	-
Yang J-K; 2020 ⁴⁸	29 Jan - 20 Mar 2020	Retrospective	China	69	61 (52-67)	34 (49.3)	0 (0.0)	NR	NR	0 (0.0)	0 (0.0)	NR	NR	FBG	6.1 (5.4- 7.0)	7.4 (6.6- 9.9)***	-
Zhang J; 2020 ⁴⁹	1 Jan - 17 Mar 2020	Retrospective	China	312	57 (38-66)	140 (44.9)	84 (26.9)	89 (28.5)	15 (4.8)	22 (7.1)	8 (2.6)	12 (3.8)	12 (3.8)	FBG	NR	NR	-
Zhang Q; 2020 ⁵⁰	3 Jan - 14 2020	Retrospective	China	74	62 (56-72)	36 (48.6)	74 (100)	35 (47.3)	2 (2.7)	13 (17.6)	NR	7 (9.5)	NR	FBG	7.35 (5.91- 10.65)	9.67 (7.72- 12.88)*	?
Zhang Y; 2020 ²⁰	29 Jan - 12 Feb 2020	Retrospective	China	258	64 (56-70)	138 (53.5)	63 (24.4)	98 (38)	12 (4.7)	39 (15.1)	9 (3.5)	12 (4.7)	9 (3.5)	FBG	NR	NR	-
Zhang Y(1); 2020 ⁵¹	8 Feb - 21 Mar 2020	Retrospective	China	166	62.7±14.2	85 (51.2)	61 (36.8)	76 (45.8)	12 (7.2)	30 (18.1)	9 (5.4)	3 (1.8)	19 (11.4)	FBG	NR	NR	-
Zhou J; 2020 ⁵²	1 Jan - 24 May 2020	Retrospective	Hong Kong	1043	35 (32-37)	563 (54)	54 (10.1)	108 (20.2)	NR	10 (1.87)	21 (3.9)	NR	230 (43)	RBG	5.33 (4.78- 6.45)	5.87 (5.87- 6.06)	+
Zhu B; 2020 ²¹	Jan 2020 - 23 Feb 2020	Retrospective	China	107	59.49±13.33	54 (50.5)	13 (12.1)	29 (27.1)	NR	10 (9.3)	NR	NR	NR	FBG	5.9 (5.4- 7.3)	7.0 (6.4- 8.2)**	-
Zhu B(1); 2020 ⁵³	17 Jan - 22 Feb 2020	Retrospective	China	293	49 (37-55.5)	151 (51.5)	0 (0.0)	NR	NR	NR	NR	NR	NR	FBG	5.3 (4.8- 5.9)	7.35 (5.6- 9.58)***	?

*p<0.05, **p<0.01, ***p<0.001 vs COVID-19 patients with good outcome.

^aUnless otherwise specified, data are presented in n(%), mean±SD, or median (IQR). ^bIncludes patient with severe/critical COVID-19 and/or death. ^cAssessed using the Quality in Prognostic Studies (QUIPS) tool, +, high risk of bias; **?**, moderate risk of bias; -, low risk of bias.

CLD, chronic lung disease; CKD, chronic kidney disease; CVD, cardiovascular disease; DM, diabetes mellitus; FBG, fasting blood glucose; IQR, interquartile range; NR, not reported; RBG, random blood glucose; SD, standard deviation. USA, United States of America.



	Study participation: description of source of population or population of interest	Study participation: adequate description of sampling frame and recruitment	Study participation: adequate description of recruitment period	Study participation: adequate description of place of recruitment	study participation: adequate description of inclusion and exclusion criteria	Study participation: adequate participation in the study by eligible individuals	Study participation: description of baseline study sample	Study attrition: adequate response rate for study participants	Study attrition: description of attempts to collect information on participants who dropped out	Study attrition: reasons for loss to follow-up provided	Study attrition: adequate description of participants lost to follow-up	Study attrition: no important differences between participants who completed the study and those who did not	Blood glucose measurement: a clear definition or description of blood glucose measured is provided	Blood glucose measurement: method of blood glucose measurement is adequately valid and reliable	Blood glucose measurement: continuous variables reported or appropriate cut points used	Blood glucose measurement: method and setting of measurement of blood glucose is the same for all study participants	Blood glucose measurement: adequate proportion of the study sample has complete data for blood glucose variable	Outcome measurement: clear definition of the outcome provided	Outcome measurement: method of outcome measurement used is adequately valid and reliable	Outcome measurement method and setting of outcome measurement is the same for all study participants	Study confounding: important confounders are measured	Study confounding: clear definitions of the important confounders measured are provided	Study confounding: measurement of confounders is adequately valid and reliable	Study confounding: same method and setting of confounding measurement in all study participants	Study confounding: appropriate methods are used if imputation is used for missing confounder data	Study confounding: important potential confounders are accounted for in the study design	Study confounding: important potential confounders are accounted for in the analysis	Statistical analysis and reporting: sufficient presentation of data to assess the adequacy of the analysis	Statistical analysis and reporting: the selected statistical model is adequate for the design of the study
Berenguer J; 2020	•	•	?	•	?	•	•	•	•	•	•	•	?	•	?	•	•	•	•	•	•	•	•	•	•	?	?	•	•
Bode B; 2020	•	•	•	?	?	•	•	•	•	•	•	•	?	•	•	•	?	•	•	•	?	?	•	•	•	?	?	?	•
Cai Y; 2020		•		•	•	•	?	•	•	•	•	•	•	•	•	•	•	•	•	•	•	•	•	•	?	?	•	•	•
Cariou B; 2020		•	•		•	•			•	?		•	~	•	•	•	*	•	•	•	•	*	•	•	-	*	0	•	•
Chang MC; 2020		*			7	•			•	•		•	•	-	•	•		•	•	•	•	•	9	•	•	?	•	•	•
Copennix, 2020						•				-		-	-	-	-	-	-		-	-	-	•		-	-	•	9	-	-
Eadini PG: 2020					2			2		-				-	-	-	2		-	-	-		•		-	2	•	-	2
Gao S: 2020		2		2											-	•	•	2	-	-	-		•		-	2	•	-	
Gunta R: 2020			2										-	2	-	•			•	•	-		•	-	-	2	•	•	2
Han M: 2020					2				•	•			•		•	•	•		•	•	•	-	•	•	?	2	•	•	•
Huang R; 2020		?		•	?	•	•		•	•	•		?	•	?	•	•		•	•	•	•	•	•	•	?	•	•	
lacobellis G; 2020	•	?	•	•	?	?	•	•	•	•	•	•	?	•	?	•	•	•	•	•	•	?	•	•	•	?	•	?	?
Li H; 2020	•	•	•	•	•	•	?	•	•	•	•	•	•	•	•	•	•	•	•	•	•	•	•	•	•	?	•	•	•
Liu SP; 2020	•	•	•	•	?	•	•	•	•	•	•	•	•	•	•	•	•	•	•	•	•	?	•	•	•	?	•	•	?
Li Y; 2020	•	•	•	•	•	•	•	•	•	•	?	?	•	•	•	•	•	•	•	•	•	•	•	•	•	?	•	•	•
Long Q; 2020	•	•	•	•	?	•	•	•	•	•	•	•	•	•	•	•	•	•	•	•	•	•	•	•	•	?	•	•	•
Marcos M; 2020	•	?	•	•	?	•	•	•	•	•	•	•	?	?	•	•	•	•	•	•	•	•	•	•	•	?	•	•	?
Mejía-Vilet JM; 2020	•	٠	•	•	•	•	?	•	•	•	•	•	?	•	?	•	٠	?	•	•	•	•	•	•	•	•	•	•	•
Sardu C; 2020	•	?	?	•	•	•	•	•	•	•	•	•	?	•	•	•	•	•	•	•	•	?	•	•	•	?	•	•	?
Shi Q; 2020	•	?	•	•	?	•	•	•	•	?	•	•	•	•	•	•	•	•	•	•	•	•	•	•	•	?	?	•	•
Smith SM; 2020	•	•	•	•	?	•	•	•	•	•	•	•	•	•	•	•	•	•	•	•	•	?	•	•	•	?	•	•	•
Tu Y; 2020	•	?	•	•	•	•	?	•	•	•	•	•	?	•	•	•	•	•	•	•	•	?	•	•	•	?	?	•	•
Wang F; 2020	?	?	•	?	?	•	•	•	•	•	•	•	•	•	?	•	•	•	•	•	•	•	•	•	•	?	•	•	•
Wang S; 2020	•	•	•	•	•	•	•	•	•	•	•	•	•	•	•	•	•	•	•	•	•	•	•	•	?	?	•	•	•
Wu C; 2020		?	•	•	?	•	•	•	?	?	•	•	?	•	•	•	•	•	•	•	•	•	•	•	•	?	?	•	•
Wu J; 2020		•	•	•	•	•	•	•	•	•	•	•	•	•	•	•	•	•	•	•	•	?	•	•	•	?	•	•	•
Yang J-K; 2020		•	•	•	•	•	•	•	•	•	•	•	•	•	•	•	•		•	•	•	?		•	•	?		•	•
Yan Y; 2020		•			•								•	•	*		•		•		•	•		•	•	•		•	
Znang J; 2020		* 2			•								•	•	•	•	•		•	•	•	•	•	•	•	*	•	•	2
Zhang V: 2020					•									-	-	•	-			-	-	-	•		-	* ?	•	-	
Zhang Y (1): 2020					2									-	-	•	•		•		•	-	•		•	• ?	•	-	2
Zhou J: 2020	F				• ?	2	2						2	-		•	-	2	•	•	•	2	•	-	•	• ?	•	-	
Zhu B: 2020		?			•	•	?		•			•	•			•	•	?		•	•	?		•	•	?		•	?
Zhu B (1); 2020	•	?	•	•	•	•	•	•	•	•	•	•	•	•	•	•	•	•	•	•	•	?	•	•	•	?	•	•	?

Table S5. Pooled unadjusted estimates of high vs low meta-analysis on the association

 between admission blood glucose and outcomes of COVID-19 patients

Outcomos	Studios	Eventa	DD (059/ CI)	Het	erogeneity
Outcomes	Studies	Events/IN	KK (95% CI)	\mathbf{I}^2	Pheterogeneity
Fasting blood glucos	e				
Poor composite outcome	4 ^{16,18,49,51}	429/1184	1.68 (1.26-2.26)	88%	< 0.001
Mortality ^a	13 ^{16–} 19,33,35,38,45,46,48	797/4688	1.86 (1.53-2.27)	92%	<0.001
Severity ^a	11 ^{17–} 19,32,38,45,46,48,51,53	1270/3949	3.26 (2.17-4.90)	96%	< 0.001
ICU admission	5 ^{18,38,39,49,51}	97/1220	5.75 (1.75-18.92)	78%	0.001
Invasive ventilation	5 ^{17,18,38,49,51}	262/1216	2.17 (1.53-3.05)	0%	0.660
Acute respiratory	$3^{18,38,49}$	59/799	3.86 (1.71-8.69)	21%	0.284
distress syndrome					
Shock	$2^{18,49}$	54/667	10.09 (4.34-	0%	0.962
			23.48)		
Random blood gluco	se				
Mortality	4 ^{14,15,28,35}	203/1150	3.64 (2.49-5.31)	39%	0.175
ICU admission	$3^{14,\overline{15},40}$	185/514	1.70 (1.43-2.03)	0%	0.620
Invasive ventilation	$2^{14,15}$	53/274	3.02 (1.84-4.96)	0%	0.801

^aOverlapping populations were observed between Li et al¹⁸, Wang et al¹⁹, and Zhu et al²¹, of which Wang et al¹⁹ was prioritized for analysis due to larger sample size. **COVID-19**, coronavirus disease 2019; **ICU**, intensive care unit

			Uni	varia	nte	Mu	ltivar	iate			-	-	(GRADE			_
Outcome	k	N	+	0	-	+	0	-	Phase ^b	Study limit. ^c	Inconsist ^d	Indirect. ^e	Imprec. ^f	Pub. bias ^g	Mod- lg ES ^h	Exp-resp grad. (RR per 1 mmol/L [95% CI])	Overall quality
Prognostic factor:	Fasting	g blood glu	cose					-		-	-	-		_			_
Door composito	4	1184	4	0	0	4	0	0	1&2	\checkmark	×	\checkmark	Х	\checkmark	Х	\checkmark	$\begin{array}{c} \oplus \oplus \oplus \bigcirc \\ \text{MODERATE}^i \end{array}$
outcome	4	1184	RF (1.2	R 1.68 6-2.2	8 26)	R (1.	R 1.2	20 39)	1&2	\checkmark	ХX	\checkmark	\checkmark	\checkmark	×	X (Linear: 1.23 [0.90-1.68])	$ \bigoplus_{LOW^j} \bigcirc \bigcirc$
	17	5514	11	4	0	12	2	0	1&2	\checkmark	X	\checkmark	Х	\checkmark	Х	\checkmark	$\begin{array}{c} \bigoplus \bigoplus \bigoplus \bigcirc \\ MODERATE^k \end{array}$
Mortality	13	4794	RF (1.5	R 1.80 3.2.2	6 27)	R (1.	R 1.8 41-2.1	81 33)	1&2	\checkmark	ХХ	\checkmark	\checkmark	Х	Х	X (Linear: 1.25 [0.96-1.63])	⊕○○○ VERY LOW ¹
	15	4764	13	2	0	7	0	0	1&2	\checkmark	\checkmark	\checkmark	Х	\checkmark	Х	\checkmark	⊕⊕⊕⊕ HIGH
Severity	9	3949	RF (2.1	R 3.20 7-4.9	6 90)	R (2.	R 3.6 31-5.'	5 75)	1&2	\checkmark	×	\checkmark	Х	\checkmark	\checkmark	√ (Non-linear: 1.34 [1.27-1.41])	$ \begin{array}{c} \bigoplus \bigoplus \bigoplus \bigoplus \\ HIGH^{k,m} \end{array} $
ICU admission	5	1220	2	3	0	1	0	0	1&2	\checkmark	X	\checkmark	ХХ	\checkmark	\checkmark	\checkmark	⊕⊕⊖⊖ Low
	5	1220	RF (1.75	R 5.7: 5-18.9	5 92)				1&2	\checkmark	XX	X	ХХ	\checkmark	$\checkmark\checkmark$	X	⊕OOO VERY LOW ^k
Invasive	6	1400	3	3	0	1	0	0	1	\checkmark	\checkmark	X	Х	\checkmark	\checkmark	X	$\begin{array}{c} \oplus \oplus \bigcirc \bigcirc \\ \text{LOW} \end{array}$
ventilation	5	1216	RF (1.5)	R 2.1′ 3-3.0	7)5)				1	\checkmark	\checkmark	X	Х	\checkmark	\checkmark	X	$\oplus \oplus \bigcirc \bigcirc$ LOW ^k
	3	799	3	0	0				1	\checkmark	\checkmark	×	ХХ	Х	\checkmark	X	⊕OOO VERY LOW
ARDS	3	799	RF (1.7	R 3.80 <u>1-8.6</u>	6 59)				1	\checkmark	×	×	Х	\checkmark	\checkmark	Х	⊕OOO VERY LOW ^k
Shoele	2	667	2	0	0				1	\checkmark	×	ХX	ХХ	Х	$\checkmark\checkmark$	X	⊕OOO VERY LOW
SHOCK	2	667	RR (4.34	10.0 4-23.4)9 48)				1	\checkmark	\checkmark	XX	ХХ	\checkmark	$\checkmark\checkmark$	X	⊕OOO VERY LOW ^k
Prognostic factor:	Rando	m blood gl	ucose			r								·			
Poor composite outcome	2	1376	2	0	0	1	1	0	1	Х	\checkmark	\checkmark	Х	Х	Х	\checkmark	⊕OOO VERY LOW

Table S6. Summary of certainty of evidence as assessed with the GRADE approach^a

Montality	7	3155	5	2	0	1	1	0	1&2	Х	Х	\checkmark	Х	Х	\checkmark	\checkmark	⊕⊕OO LOW
Monanty	4	1150	RH (2.4	R 3.6 9-5.3	4 31)				1&2	Х	Х	\checkmark	Х	\checkmark	\checkmark	Х	$\begin{array}{c} \oplus \oplus \bigcirc \bigcirc \\ \text{LOW}^k \end{array}$
ICU admission	4	725	3	1	0	2	0	0	1&2	Х	\checkmark	Х	Х	\checkmark	Х	Х	⊕OOO VERY LOW
	3	514	RH (1.4	R 1.7 ·3-2.0	0)3)	1 (0	RR 1.2 .84-1.	25 84)	1&2	\checkmark	XX	\checkmark	ХХ	\checkmark	Х	Х	⊕OOO VERY LOW ^k
Invasive	3	349	3	0	0	1	0	0	1&2	Х	\checkmark	Х	Х	Х	\checkmark	Х	⊕OOO VERY LOW
ventilation	2	274	RF (1.8	R 3.0	2 96)				2	Х	\checkmark	Х	ХХ	Х	\checkmark	Х	⊕OOO VERY LOW ^k
ARDS	2	300	1	0	0	1	0	0	1	Х	\checkmark	X	Х	Х	Х	X	⊕OOO VERY LOW

^aFor qualitative assessments: +, number of studies reporting significant effects with a positive value; 0, number of studies reporting nonsignificant effects; -, number of studies reporting significant effects with a negative value. For GRADE factors: \checkmark , no serious limitations; X, serious limitations (or not present for moderate/large effect size and exposure-response gradient); X X, very serious limitations (downgraded by two levels). For overall quality: high, we are very confident that the true effect lies close to that of the estimated effect; moderate, we are moderately confident in the effect estimate and the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different; low, confidence in the effect estimate is limited and the true effect is likely to be substantially different from the estimate of the effect; very low, we have very little confidence in the effect estimate and the true effect is likely to be substantially different from the estimate of effect

^bGRADE assessment of outcomes with phase 1 and 2 studies starts with high quality of evidence, while assessment of outcomes with only phase 1 studies starts with moderate quality of evidence.⁵⁴

^cDowngraded for study limitation by one level when >50% studies yielded moderate-to-high risk of bias and by two levels when >50% studies yielded high risk of bias

^dDowngraded for inconsistency by one level for observed heterogeneity ($I^2=25-75\%$) or minimal overlapping confidence intervals ($P_{heterogeneity} < 0.10$) and two levels for substantial unexplained heterogeneity ($I^2 > 75\%$) or no overlapping confidence intervals

^eDowngraded for indirectness in population by one level when >50% of studies only enrolled severe patients and by two levels when all studies only included severe patients

^fDowngraded for imprecision due to small number of samples/studies and/or wide confidence intervals

^gFor qualitative summary, results were downgraded for publication bias when the number of samples/studies were relatively small, yielded wide confidence intervals or equivocal estimates.

^hUpgraded for moderate or large effect size by one level when RR>2 and by two levels when RR>5⁵⁵

ⁱAlthough meta-analysis failed to detect exposure-response gradient, qualitative assessment of eligible studies (i.e. Fadini et al¹⁶ and Zhang et al⁴⁹) indicated significant exposure-response gradient

^jAlthough meta-analysis failed to detect exposure-response gradient, qualitative assessment of eligible studies (i.e. Li et al¹⁸, Zhang et al, Wang et al) indicated significant exposure-response gradient

^kNot downgraded as publication bias could not be assessed due to insufficient number of studies (n<10)⁶

¹Downgraded for publication bias as funnel plot asymmetry was observed (see Appendix Figure S4; Egger's test: p<0.001; Begg's test: p=0.245)

^mAlthough considerable heterogeneity was observed ($I^2=78\%$, p<0.001), we only downgraded by one level as analysis based on risk of bias explained all heterogeneity.

Exp-resp grad., exposure-response gradient; **GRADE**, the Grading of Recommendations Assessment, Development and Evaluation tool; **ICU**, intensive care unit; **Imprec.**, imprecision; **Inconsist.**, inconsistency; **Indirect.**, indirectness; **k**, number of studies; **Mod-lg ES**, moderate or large effect size; **N**, number of participants; **Phase**, phase of investigation; **Pub. bias**, publication bias; **RR**, risk ratio; **Study limit.**, study limitation.

Location	Cai Y ²⁹	Deng M ³²	Gao S ³³	Han M ³⁵	Huang R ³⁶	Li H ¹⁸	Li Y ³⁸	Liu SP ³⁹	Long Q ¹⁷	Shi Q ⁴¹	Τu Υ ⁴³	Wang F ⁴⁴	Wang S ¹⁹	Wu C ⁴⁵	Wu J ⁴⁶	Yan Y ⁴⁷	Yang J-K ⁴⁸	Zhang J ⁴⁹	Zhang Q ⁵⁰	Zhang Y ²⁰	Zhang Y(1) ⁵¹	Zhu B ²¹	Zhu B(1) ⁵³
China																			-				
General Hospital of																							
the Yangtze River																							
Shipping																							
Huai'an No. 4																							
People's Hospital																							
Hubei Provincial																							
Hospital of																							
Integrated Chinese																							
& Western Medicine																							
Hubei Provincial																							
Hospital of																							
Traditional Chinese																							
Medicine																							
Infectious Disease																							
Hospital of Sugian																							
Jin Yin-tan Hospital ^c																							
Renmin Hospital of																							
Wuhan University ^c																							
Ruian People's																							
Hospital																							
The Affiliated																							
Hospital of Xuzhou																							
Medical University																							
The Affiliated																							
Infectious Diseases																							
Hospital of Soochow																							
University																							
The First Affiliated																							
Hospital of																							
Wenzhou Medical																							
University																							
The First People's																							
Hospital of																							
Lianyungang																							
The Second																							
Affiliated Hospital of	1														1								
Wenzhou Medical	1														1								
University																							
The Third People's																							
Hospital of	1														1								
Changzhou																			1	1	1		

Table S7. Locations of included studies originating from China^{a,b}

The Third People's	
Wenzhou Central	
Wenzhou Sixth	
People's Hospital	
Wuhan Fifth	
Hospital	
Wuhan Third	
Hospital ^e	 ↓
Wuhan Hankou	
	 ╞────
Vunan Red Cross	
Horital	
Wuhan Union	
Hospital	
Wuchang Wuchang	
Hospital	
Yancheng Second	
People's Hospital	
Zhongnan Hospital	
of Wuhan	1

^aOverlapping populations were determined from: (1) study location, (2) recruitment period (see Table SX), and (3) co-overlapping authors⁹.

^bStudies originating from outside China was not shown as no potential overlapping populations were detected. ^cNo overlapping populations were detected as we did not observe any overlapping co-authors. ^dPossible overlapping populations were observed between Li et al¹⁸, Wang et al¹⁹, Zhang et al²⁰, and Zhu et al²¹ (as confirmed by the authors).

Figure S2. Leave-one-out sensitivity analysis of high vs low meta-analysis between admission fasting blood glucose and outcomes on (A) poor outcome, (B) mortality and (C) severity. Solid vertical lines refer to the pooled overall estimates, while dashed vertical lines refer to the 95% confidence interval of the estimates.

(A) Fasting blood glucose: Poor outcome

Study				Risk I	Ratio			12	2 (%)	RR [95% CI]
Fadini GP; 2020 Zhang J; 2020 (≥7.0 vs <5.6) Zhang Y(1); 2020 (≥7.0 vs <7.0) Li H; 2020									88 82 77 87	2.27 [0.86, 6.00] 1.15 [1.02, 1.30] 1.14 [1.03, 1.26] 2.30 [0.91, 5.84]
	0	1	2	3	4	5	6	7		

(B) Fasting blood glucose: Mortality

Study		F	Risk Rat	io		l2 (%)	RR [95% CI]
Cai Y; 2020 (≥7.0 vs <7.0) Chang MC; 2020 Fadini GP; 2020 (/2) Han M; 2020 (≥7.0 vs <7.0) Li Y; 2020 Long Q; 2020 (≥6.1 vs <6.1) Wang S; 2020 (≥7.0 vs <6.1) Wu J; 2020 (≥6.1 vs <6.1) Yang JK; 2020 (≥7.0 vs <7.0) Zhang J; 2020 (≥7.0 vs <5.6)	ſ 1		2.5	1	3.5	 87 84 86 86 86 85 87 87 87 86	1.78 [1.37, 2.30] 2.34 [1.53, 3.56] 2.36 [1.51, 3.69] 1.71 [1.33, 2.19] 1.70 [1.34, 2.17] 1.78 [1.37, 2.30] 1.71 [1.33, 2.20] 1.80 [1.39, 2.34] 1.74 [1.36, 2.24] 1.70 [1.34, 2.17]

(C) Fasting blood glucose: Severity

Study		Risk Ra	tio		l2 (%)	RR [95% Cl]
Li Y; 2020 (≥6.1 vs <6.1) Liu S; 2020 (≥11.1 vs <7.0) Wang S; 2020 (≥7.0 vs <6.1) Wu J; 2020 (≥6.1 vs <6.1) Yang JK 2020 (≥7.0 vs <7.0) Zhang J; 2020 (≥7.0 vs <5.6) Zhu B(1); 2020 (>7.05 vs 4.74-5.21)		- • - • - • - • - • - • - • • - • • • • •		 '	82 71 79 81 81 81 66	4.13 [2.36, 7.23] 3.00 [2.00, 4.49] 4.46 [2.35, 8.44] 4.40 [2.50, 7.74] 3.56 [2.19, 5.79] 3.86 [2.24, 6.64] 2.91 [2.02, 4.20]
1	3	5	7	9		

Figure S3. Contour-enhanced funnel plot with pseudo 95% confidence interval indicating evidence of publication bias (as shown by asymmetry) for high vs low meta-analysis evaluating admission fasting blood glucose level and mortality in COVID-19 patients



Figure S4. Linear dose-response relationship between admission FBG level and mortality in non-diabetic COVID-19 patients. FBG, fasting blood glucose

Study	TE	seTE	Risk Ratio	RR	95%-CI	Weight
Zhang J; 2020	0.45	0.1685		1.57	[1.13; 2.19]	17.9%
Fadini GP; 2020	0.30	0.0931	+ • •	1.55	[1.10, 1.58] [0.95; 1.37]	43.9% 38.2%
Random effects model	- 0.00	27 0 17		1.30	[1.11; 1.53]	100.0%
Heterogeneity: $T = 44\%$, τ	= 0.008	p = 0.17 . 0.5	1 2			

			Risk ratio (95% CI) ^a			
Author; Year	Outcome	Adjusted variables	Cut-off (mmol/L)	Unadjusted	Adjusted	
Poor composite	outcome					
Fadini PG; 2020	ICU, IV, or Death	Age, Sex, Clinical (CKD, Steroid)	+2	1.21 (1.11-1.32)	1.15 (1.07-1.23)	
Li H; 2020	Severity, or Death	Age, Sex	7.0	1.34 (1.20-1.50) ^b	1.09 (1.06-1.13) ^c	
Zhang I: 2020	ICU, IV, or	Age Say Hospital Clinical (Comorbidities)	≥7.0 vs <5.6	5.70 (2.80-11.63) ^b	3.53 (1.48-8.41) ^d	
Zinang J, 2020	Death	Age, Sex, Hospital, Clinical (Comorbidities)	5.6-6.9 vs <5.6	3.27 (1.43-7.51) ^b	1.42 (0.53-3.81) ^d	
Zhang Y(1); 2020	ICU, IV, or Death	Age, Sex, Clinical (BMI, Cancer, CVD, Hypertension)	7.0	2.75 (1.11-6.81) ^b	3.70 (1.73-7.93) ^d	
Mortality	•					
Cai Y; 2020	In-hospital mortality	Age, Clinical (ARDS, CKD, COPD, CVD, Diabetes, Hypertension), Laboratory (Creatinine, CRP, Leukocyte count, PCT)	7.0	3.15 (2.17-4.56) ^d	2.11 (1.15-3.88) ^d	
Chang MC; 2020		Age, Clinical (CLD, Diabetes), Laboratory (WBC)	NR		1.01 (1.00-1.02) ^d	
Fadini PG; 2020		Age, Sex	+2	1.15 (1.03-1.30)	1.03 (0.91-1.16) ^c	
Goo St 2020			≥6.1 vs <3.9	0.72 (0.06-9.34) ^b		
Gao 5; 2020			3.9-6.1 vs <3.9	0.56 (0.04-7.41) ^b		
	Hospitalized	Age Clinical (SOEA score) Laboratory (D	7.0		2.90 (1.51-5.58) ^e	
Han M; 2020	death	dimer, Lymphocyte)	≥11.1 vs <7.0	5.04 (3.03-8.38) ^b		

Table S8. Outcomes on the association of admission fasting blood glucose and prognosis of COVID-19 patients

			7.0-11.1 vs <7.0	2.44 (1.34-4.44) ^b	
L ; H. 2020	All-cause	Age, Sex, Smoking, Clinical (SBP), Laboratory	≥7.0 vs <5.6	14.04 (3.36-58.64) ^b	9.43 (2.18-40.6) ^d
LI H; 2020	mortality	(Total cholesterol)	5.6-6.9 vs <5.6	3.07 (0.63-14.93) ^b	2.84 (0.57-14.1) ^d
Li Y; 2020	In-hospital mortality	Laboratory (D-dimer)	11.0	3.73 (1.30-8.53) ^b	5.66 (1.84-17.39) ^e
Long Q; 2020	In-hospital mortality	Age, Laboratory (BUN)	6.1	1.76 (1.48-2.05) ^e	1.96 (1.25-3.07) ^c
Shi Q; 2020	In-hospital mortality		NR	DM: 1.12 (1.05- 1.19) ^d Non-DM: 1.13 (1.02-1.25) ^d	
NU G 2020	28-day mortality	Age, Sex, Clinical (CRB-65 score)	≥7.0 vs <6.1	3.54 (2.33-5.38) ^d	2.30 (1.49-3.55) ^d
Wang S; 2020			6.1-6.9 vs <6.1	1.71 (0.99-2.94) ^d	2.06 (1.20-3.54) ^d
Wu C; 2020			NR	$1.00 (0.92 - 1.08)^d$	
Wu J; 2020	In-hospital mortality	Age, Sex, Smoking, Clinical (Cancer, CKD, COPD, Corticosteroid, Diabetes, Hypertension, Insulin), Laboratory (ALT, AST, Creatinine, D- dimer, Lymphocyte, WBC)	6.1	2.21 (1.43, 3.43) ^d	1.84 (1.14-2.97) ^d
Yang J-K; 2020	In-hospital mortality	Sex	7.0	5.10 (1.77-14.7) ^d	3.75 (1.26-11.16) ^d
Zhang I: 2020		Age Sey Hegnital Clinical (Comerkidities)	$\frac{\geq}{7.0 \text{ vs}}$	9.88 (3.49-27.98) ^b	6.25 (1.91-20.45) ^d
Znang J; 2020		Age, Sex, Hospital, Chinical (Comorbidities)	5.6-6.9 vs <5.6	6.02 (1.92-18.86) ^b	4.11 (1.15-14.74) ^d
Zhang Y; 2020		Age, Clinical (CKD, CVD), Laboratory (CRP, Eosinophil, Leukocytes, Lymphocyte,	6.1		$1.19 (1.08-1.31)^d$

		Neutrophil-to-lymphocyte ratio, Neutrophils, PCT)			
Zhang Y(1); 2020			7.0	1.50 (0.44-5.17) ^e	
Zhu B; 2020		Age, Sex, Clinical (BMI, DBP, SBP), Laboratory (HDL, Total cholesterol, Triglyceride)	7.0	2.65 (0.99-7.12) ^f	3.53 (0.59-21.15) ^d
Severity					
Deng M; 2020	Severe/Critical		6.1	6.13 (2.53-9.26) ^e	
		Age, Sex	7.0		1.09 (1.06-1.12) ^c
	Severe/Critical		≥7.0 vs <5.6	1.46 (1.25-1.70) ^b	
			5.6-6.9 vs <5.6	1.17 (0.99-1.40) ^b	
	ICU		\geq 7.0 vs <5.6	7.72 (1.75-34.04) ^b	
			5.6-6.9 vs <5.6	4.09 (0.89-18.91) ^b	
Li H; 2020	IV		≥7.0 vs <5.6	5.14 (1.48-17.95) ^b	
			5.6-6.9 vs <5.6	2.05 (0.52-8.01) ^b	
	01 1		≥7.0 vs <5.6	10.30 (3.17-33.41) ^b	
	Snock		5.6-6.9 vs <5.6	2.05 (0.52-8.01) ^b	
			\geq 7.0 vs <5.6	14.04 (1.83- 107.84) ^b	
	ARDS		5.6-6.9 vs <5.6	4.09 (0.46-36.13) ^b	

	In-hospital complication	Imaging (HRCT score)	6.1	1.26 (0.33-4.78)	2.44 (1.43-4.18) ^e
Li Y; 2020	ICU		11.0	2.33 (0.98-5.53) ^b	
	IV		11.0	2.04 (0.35-11.78) ^b	
	ARDS		11.0	2.52 (1.08-5.91) ^b	
			≥11.1 vs	24.22 (11.42-	1155(1152)
		Age, Sex, Duration of illness, Clinical	<7.0	51.41) ^d	11.33 (4.43-29.98)
Liu S; 2020	ICU	(Diabetes), Laboratory (D-dimer, IL-6)	7.0-11.1 vs	9 45 (4 050 17 62) ^d	5 54 (2 22 12 51) ^d
			<7.0	8.43 (4.030-17.03)*	5.54 (2.25-15.51)*
			NR		1.56 (1.29-1.88) ^d
Long Q; 2020	IV		6.1	1.96 (1.31-2.79) ^c	
Smith SM:			↑FBG betwe	en intubated vs non-ir	tubated patients
2020	IV		(MD: 74.3 mmol/L [95% CI: 9.02-135.9 mmol/L], p=0.013)		
2020					
	In-hospital complication		≥7.0 vs	$2.24(1.80.2.70)^{b}$	$2.24(1.01.2.63)^{e}$
Wang S: 2020			<5.6	2.24 (1.00 2.17)	2.24 (1.)1 2.03)
wang 5, 2020			5.6-6.9 vs	$1.84(1.40-2.41)^{b}$	$1.84 (1.41-2.33)^{e}$
			<5.6	1.04 (1.40-2.41)	1.04 (1.41-2.33)
Wu C; 2020	ARDS		NR	1.13 (1.08-1.19) ^d	
Wu J; 2020	Critical (IV, Shock, or ICU admission)	Age, Sex, Smoking, Clinical (Cancer, CKD, COPD, Diabetes, Hypertension, Insulin, Systemic glucocorticoids), Laboratory (ALT, AST, Creatinine, D-dimer, Lymphocyte, WBC)	6.1	2.08 (1.69-2.56) ^d	1.84 (1.14 to 2.97) ^d
Yang J-K; 2020	Critical (IV, Shock, or ICU)	Laboratory (HBDH)	7.0	2.97 (1.09-8.11) ^e	4.82 (1.18-11.06) ^e
Zhang I: 2020	In-hospital	Age Say Hospital Clinical (Comorbidition)	≥7.0 vs <5.6	3.50 (1.87-6.55) ^b	3.26 (1.85-5.75) ^e
Zhang J; 2020	complication	omplication Age, Sex, Hospital, Clinical (Comorbidities)	5.6-6.9 vs <5.6	2.27 (1.07-4.79) ^b	2.50 (1.17-4.69) ^e

			≥7.0 vs <5.6	2.63 (0.60-11.50) ^b	
	icu		5.6-6.9 vs <5.6	1.76 (0.31-10.43) ^b	
	11/		≥7.0 vs <5.6	2.96 (0.50-17.40) ^b	6.33 (1.87-21.48) ^e
	IV		5.6-6.9 vs <5.6	2.68 (0.39-18.60) ^b	1.66 (0.42-6.54) ^e
	Sheak		≥7.0 vs <5.6	9.88 (2.94-33.19) ^b	
	SHOCK		5.6-6.9 vs <5.6	4.46 (1.10-18.12) ^b	
			≥7.0 vs <5.6	4.61 (1.22-17.38) ^b	
	AKDS		5.6-6.9 vs <5.6	1.78 (0.31-10.43) ^b	
\mathbf{Z}	Severe/Critical		7.0	1.19 (0.97-1.29) ^b	
Znang $Y(1)$;	ICU		7.0	6.15 (0.76-49.94) ^b	
2020	IV		7.0	10.24 (1.34-78.23) ^b	
		e/Critical Age, Sex, Clinical (BMI), Laboratory (AST, HDL, LDH)	≥7.05 vs 4.74-5.21	40.35 (12.53- 51.29) ^e	23.85 (6.77-84.07) ^e
Zhu B(1); 2020	Source/Critical		5.78-7.05 vs 4.74- 5.21	16.27 (2.72-44.67) ^e	9.13 (1.23-36.44) ^e
	Severe/Critical		5.21-5.78 vs 4.74- 5.21	8.42 (1.16-34.48) ^e	3.03 (0.33-20.08) ^e
			<4.74 vs 4.74-5.21	12.41 (1.90-40.52) ^e	18.02 (2.69-47.82) ^e

^aUnless explicitly stated, all outcomes are presented in rate ratios along with their 95% CIs. ^bCalculated from binary data³; ^cUnpublished data, provided by request. ^dOutcomes were originally reported as hazard ratios, but we were unable to approximate the optimal minimax conversion

for the risk ratios as the outcome probability in either or both groups fell beyond the range (i.e. <20 or >80%)⁷; therefore, we decided to use the effect sizes interchangeably and explored the potential disparities by subgroup analyses. ^eCalculated using the formula provided by Cochrane handbook⁶; ^fCalculated using the formula provided by VanderWeele et al⁷.

ALT, alanine aminotransferase; ARDS, acute respiratory distress syndrome; AST, aspartate aminotransferase; BMI, body mass index; BUN, blood urea nitrogen; CCB, calcium channel blocker; CKD, chronic kidney disease; CI, confidence interval; CLD, chronic lung disease; COPD, chronic obstructive pulmonary disease; CRB-65 score, confusion-respiratory rate-blood pressure-65 score; CRP, C-reactive protein; CT, computed tomography; CVD, cardiovascular disease; DBP, diastolic blood pressure; eGFR, estimated glomerular filtration rate; HBDH, α-hydroxybutyrate dehydrogenase; HDL, high-density lipoprotein; HRCT, high-resolution computed tomography; ICU, intensive care unit; IL-6, interleukin 6; IV, invasive ventilation; LDH, lactate dehydrogenase; LDL, low-density lipoprotein; MLR, monocyte-to-lymphocyte ratio; NLR, neutrophil-to-lymphocyte ratio; PCT, procalcitonin; SBP, systolic blood pressure; SOFA score, sequential organ failure assessment score; TG, triglyceride; WBC, white blood cells.

Table S9. Sensitivity analysis for linear dose-response meta-analysis on the associationbetween admission fasting blood glucose concentration and mortality and severity inCOVID-19 patients

	Lower open-ended category	Upper open-ended category	RR (95% CI) per 1 mmol/L increase
Mortality ^a			
Primary analysis	Midpoint between UB and 3.9 mmol/L	LB + 1.5 x width of adjacent category	1.25 (0.96-1.63)
Non-diabetic			1.30 (1.11-1.53)
patients			
Severity		ID 15 14 0	1 22 (1 26 1 40)
Primary analysis	UB and 3.9 mmol/L	$LB + 1.5 \times \text{width of}$ adjacent category	1.33 (1.26-1.40)
Non-diabetic			1.36 (1.28-1.44)
patients			
Model 1	Midpoint between	25% higher than LB	1.25 (1.20-1.29)
Model 2	Midpoint between UB and 3.9 mmol/L	50% higher than LB	1.17 (1.12-1.21)
Model 3	Midpoint between UB and 3.9 mmol/L	LB + 0.5 x width of adjacent category	1.41 (1.33-1.49)
Model 4	Midpoint between UB and 3.9 mmol/L	LB + 1.0 x width of adjacent category	1.37 (1.29-1.44)
Model 5	Midpoint between UB and 3.9 mmol/L	LB + 2.0 x width of adjacent category	1.29 (1.21-1.38)
Model 6	UB - 0.5 x width of adjacent category	25% higher than LB	1.30 (1.24-1.36)
Model 7	UB - 0.5 x width of adjacent category	50% higher than LB	1.18 (1.14-1.21)
Model 8	UB - 0.5 x width of adjacent category	LB + 0.5 x width of adjacent category	1.51 (1.22-1.86)
Model 9	UB - 0.5 x width of adjacent category	LB + 1.0 x width of adjacent category	1.43 (1.21-1.70)
Model 10	UB - 0.5 x width of adjacent category	LB + 1.5 x width of adjacent category	1.38 (1.19-1.60)
Model 11	UB - 0.5 x width of adjacent category	LB + 2.0 x width of adjacent category	1.34 (1.17-1.53)
Model 12	UB - 1.0 x width of adjacent category	25% higher than LB	1.28 (1.23-1.34)
Model 13	UB - 1.0 x width of adjacent category	50% higher than LB	1.17 (1.14-1.21)
Model 14	UB - 1.0 x width of adjacent category	LB + 0.5 x width of adjacent category	1.46 (1.24-1.73)
Model 15	UB - 1.0 x width of adjacent category	LB + 1.0 x width of adjacent category	1.40 (1.22-1.62)
Model 16	UB - 1.0 x width of adjacent category	LB + 1.5 x width of adjacent category	1.36 (1.20-1.54)

Model 17	Model 17UB - 1.0 x width of		1.33 (1.18-1.49)
	adjacent category	adjacent category	

^aSensitivity analysis for mortality outcome was not conducted as the primary outcome failed to exhibit exposure-response gradient

Figure S5. Sensitivity analysis for non-linear dose-response meta-analysis of severity outcome according to location of knots



Admission FBG level, mmol/L

			Risk ratio (95% CI) ^a			
Author; Year	Outcome	Adjusted variables	Cut-off (mmol/L)	Unadjusted	Adjusted	
Poor composite	outcome		•		•	
Cariou B; 2020	IV or death	Age, Sex, Clinical (BMI, Dyspnea), Laboratory (AST, CRP, eGFR, Lymphocyte, Platelet)	+1SD	OR 1.28 (1.12- 1.24)	OR 1.14 (0.92-1.42)	
Sardu C; 2020	ICU, IV, or Death	Age, Sex, Smoking, Clinical (ACEI, Aspirin, β - blocker, Blood pressure, BMI, CCB, CVD, Dyslipidemia, Heart rate, Hypertension, Thiazide diuretics), Laboratories (Cholesterol, HDL, LDL, TG)	7.7	RR 3.54 (1.45- 8.64) ^b	HR 3.51 (1.04- 11.90)	
Mortality						
Bode B; 2020	In-hospital mortality		10.0	4.63 (2.96-7.26) ^b		
Cariou B; 2020	7-day mortality	Age, Sex, Clinical (Ageusia, Cephalalgia, Dyspnea, Rhinitis), Laboratory (AST, CRP, eGFR, Platelet, WBC)	+1SD	OR 1.20 (0.98- 1.46)	OR 1.30 (0.94-1.82)	
		Age, Sex, Clinical (CKD, Cognitive impairments, COPD, Hypertension, Stroke), Laboratory (D-dimer, Lymphocyte)	>7.84 vs <7.78	2.19 (1.27-3.81) ^c	2.39 (1.10-5.19) ^c	
Compelli A.				Q5 vs Q1	HR 2.32 (0.91- 5.96)	HR 1.70 (0.49-5.90)
2020		Age, Sex, Clinical (CKD, COPD, Cognitive	Q4 vs Q1	HR 3.57 (1.46- 8.76)	HR 5.91 (1.73- 20.19)	
		(Lymphocyte, Prothrombin)	Q3 vs Q1	HR 1.83 (0.69- 4.88)	HR 3.87 (1.04- 14.43)	
			Q2 vs Q1	HR 1.37 (0.49- 3.85)	HR 1.50 (0.37-5.08)	
Han M; 2020	Hospitalized death	Age, Clinical (SOFA score), Laboratory (D- dimer, Lymphocyte)	$\geq 11.1 \text{ vs}$ <7.0	2.84 (1.76-4.56) ^b		

Table S10. Outcomes on the association of admission random blood glucose and prognosis of COVID-19 patients

Sardu C; 2020			7.0-11.1 vs <7.0 7.7	1.49 (0.89-2.47) ^b 6.80 (0.85-54.65) ^b	
Severity	-		•	· · · · · · · · · · · · · · · · · · ·	•
Connelli A	ICU		7.78	1.88 (1.28-2.77) ^b	
Coppend A;	IV		7.78	2.92 (1.66-5.13) ^b	
2020	ARDS		7.78	1.80 (1.32-2.44) ^b	
Iacobellis G; 2020	ARDS	Age, Sex, Temperature			β 0.912 (0.91-0.92)
Mejía-Vilet JM; 2020	ICU	Sex, Clinical (Charlson comorbidity index, Dyspnea, Respiratory rate, SBP), Laboratory (Albumin, LDH, S/F ratio), Imaging (Lung CT value)	11.1	1.65 (1.30-1.93) ^d	1.57 (1.16-2.11) ^d
	ICU, IV		7.7	2.72 (0.92-8.04) ^b	
Sardu C; 2020	ICU		7.7	4.08 (0.45-36.95) ^b	
	IV		7.7	3.40 (1.20-9.60) ^b	
Tu Y; 2020 ^d	IV	Age, Laboratory (D-dimer, LDH, MLR, WBC)		β -0.33 (-0.58, - 0.08)	β-0.27 (-0.49, -0.05)
Zhou J; 2020	ICU	Age, Sex, Residence districts, Clinical (Comorbidities)	NR		1.05 (1.04-1.06) ^d

^aUnless explicitly stated, all outcomes are presented in rate ratios along with their 95% CIs. ^bCalculated from binary data³. ^cOutcomes were originally reported as hazard ratios, but we were unable to approximate the optimal minimax conversion for the risk ratios as the outcome probability in either or both groups fell beyond the range (i.e. <20 or >80%)⁷; therefore, we decided to use the effect sizes interchangeably and explored the potential disparities by subgroup analyses. ^dCalculated using the formula provided by Cochrane handbook⁶; ^eCalculated using the formula provided by VanderWeele et al⁷.

ACEI, angiotensin-converting-enzyme inhibitor; ARDS, acute respiratory distress syndrome; AST, aspartate aminotransferase; BMI, body mass index; CCB, calcium channel blocker; CI, confidence interval; CKD, chronic kidney disease; CRP, C-reactive protein; CT, computed tomography; CVD, cardiovascular disease; eGFR, estimated glomerular filtration rate; HDL, high-density lipoprotein; ICU, intensive care unit;

IV, invasive ventilation; LDH, lactate dehydrogenase; LDL, low-density lipoprotein; S/F ratio, SpO₂/FiO₂ ratio; SBP, systolic blood pressure; SOFA score, sequential organ failure assessment score; TG, triglyceride; β -blocker, beta-blocker

Supplementary References

- 1. Riley RD, Moons KGM, Snell KIE, Ensor J, Hooft L, Altman DG, et al. A guide to systematic review and meta-analysis of prognostic factor studies. BMJ. 2019;364.
- 2. Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials. 2007 Jun 7;8:16.
- Viera AJ. Odds ratios and risk ratios: what's the difference and why does it matter? South Med J. 2008 Jul;101(7):730–4.
- 4. Hayden JA, Côté P, Bombardier C. Evaluation of the quality of prognosis studies in systematic reviews. Ann Intern Med. 2006 Mar 21;144(6):427–37.
- Kumaravel B, Bachmann MO, Murray N, Dhatariya K, Fenech M, John WG, et al. Use of haemoglobin A1c to detect impaired fasting glucose or Type 2 diabetes in a United Kingdom community based population. Diabetes Res Clin Pract. 2012;96:211– 6.
- Higgins J, Thomas J, Chandler J, Cumpston M, Li T, Page M, et al., editors. Cochrane handbook for systematic reviews of interventions version 6.0 (updated July 2019). 6th ed. Cochrane Handbook for Systematic Reviews of Interventions. Cochrane; 2019.
- VanderWeele TJ. Optimal approximate conversions of odds ratios and hazard ratios to risk ratios. Biometrics. 2019;1–7.
- 8. Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in metaanalyses. BMJ. 2003 Sep 6;327(7414):557–60.
- Wood J. Methodology for dealing with duplicate study effects in a meta-analysis. Organ Res Methods. 2008;11(1):79–95.
- Liao WC, Tu YK, Wu MS, Lin JT, Wang HP, Chien KL. Blood glucose concentration and risk of pancreatic cancer: Systematic review and dose-response meta-analysis. BMJ. 2015;349:g7371.
- Orsini N, Bellocco R, Greenland S. Generalized least squares for trend estimation of summarized dose-response data. Stata Journal. 2006.
- Marcos M, Belhassen-Garcia M, Sanchez- Puente A, Sampedro-Gomez J, Azibeiro R, Dorado-Diaz PI, et al. Development of a severity of disease score and classification model by machine learning for hospitalized COVID-19 patients. medRxiv. 2020 Jan 1;2020.07.13.20150177.
- Berenguer J, Ryan P, Rodríguez-Baño J, Jarrín I, Carratalà J, Pachón J, et al. Characteristics and predictors of death among 4,035 consecutively hospitalized

patients with COVID-19 in Spain. Clin Microbiol Infect. 2020 Aug 4;S1198-743X(20)30431-6.

- Sardu C, D'Onofrio N, Balestrieri ML, Barbieri M, Rizzo MR, Messina V, et al. Outcomes in Patients With Hyperglycemia Affected by COVID-19: Can We Do More on Glycemic Control? Diabetes Care. 2020 Jul;43(7):1408–15.
- Coppelli A, Giannarelli R, Aragona M, Penno G, Falcone M, Tiseo G, et al. Hyperglycemia at Hospital Admission Is Associated With Severity of the Prognosis in Patients Hospitalized for COVID-19: The Pisa COVID-19 Study. Diabetes Care. 2020 Aug 10;dc201380.
- Fadini GP, Morieri ML, Boscari F, Fioretto P, Maran A, Busetto L, et al. Newlydiagnosed diabetes and admission hyperglycemia predict COVID-19 severity by aggravating respiratory deterioration. Diabetes Res Clin Pract. 2020 Aug 15;168:108374.
- Long Q, Zhou C, Wang Y, Song B, Cheng X, Dong Q, et al. Admission biochemical test associated with the prognosis of COVID-19: a multi-centered retrospective cohort study. 2020;1–19.
- Li H, Tian S, Chen T, Cui Z, Shi N, Zhong X, et al. Newly diagnosed diabetes is associated with a higher risk of mortality than known diabetes in hospitalized patients with COVID-19. Diabetes, Obes Metab. 2020 May 29;n/a(n/a).
- 19. Wang S, Ma P, Zhang S, Song S, Wang Z, Ma Y, et al. Fasting blood glucose at admission is an independent predictor for 28-day mortality in patients with COVID-19 without previous diagnosis of diabetes: a multi-centre retrospective study. Diabetologia. 2020 Jul 10;1–10.
- Zhang Y, Cui Y, Shen M, Zhang J, Liu B, Dai M, et al. Association of diabetes mellitus with disease severity and prognosis in COVID-19: A retrospective cohort study. Diabetes Res Clin Pract. 2020/05/22. 2020 Jul;165:108227.
- Zhu B, Jiang C, Feng X, Zheng Y, Yang J, Wang F, et al. Correlation between Fasting Blood Glucose Level at Admission and Mortality in COVID-19 Patients: A Retrospective Study. Res Sq. 2020;1–11.
- 22. Jiang Q, Liu Q, Chen F, Zeng X, Song F, Lu Z, et al. Reporting quality and statistical analysis of published dose-response meta-analyses was suboptimal: a cross-sectional literature survey. J Clin Epidemiol. 2019;115(July):133–40.
- Crippa A, Orsini N. Dose-response meta-analysis of differences in means. BMC Med Res Methodol. 2016;16(1):91.

- R Core Team. R: A language and environment for statistical computing. Vienna: R Foundation for Statistical Computing; 2020.
- 25. Balduzzi S, Rücker G, Schwarzer G. How to perform a meta-analysis with R: a practical tutorial. Evid Based Ment Health. 2019 Nov;22(4):153–60.
- Crippa A, Orsini N. Multivariate dose-response meta-analysis: The dosresmeta R package. J Stat Softw. 2016;72(1):1–15.
- 27. Harrel Jr FE. rms: Regression Modeling Strategies. R package version 6.0-1 [Internet].
 2020 [cited 2020 Aug 30]. Available from: https://cran.r-project.org/package=rms
- Bode B, Garrett V, Messler J, McFarland R, Crowe J, Booth R, et al. Glycemic Characteristics and Clinical Outcomes of COVID-19 Patients Hospitalized in the United States. J Diabetes Sci Technol. 2020 May 9;14(4):813–21.
- Cai Y, Shi S, Yang F, Yi B, Chen X, Li J, et al. Fasting Glucose Level Is a Predictor of Mortality in Patients with COVID-19 Independent of Diabetes History. SSRN Electron J. 2020;
- Cariou B, Hadjadj S, Wargny M, Pichelin M, Al-Salameh A, Allix I, et al. Phenotypic characteristics and prognosis of inpatients with COVID-19 and diabetes: the CORONADO study. Diabetologia. 2020/05/29. 2020 Aug;63(8):1500–15.
- Chang MC, Hwang J-M, Jeon J-H, Kwak SG, Park D, Moon JS. Fasting Plasma Glucose Level Independently Predicts the Mortality of Patients with Coronavirus Disease 2019 Infection: A Multicenter, Retrospective Cohort Study. J Korean Endocr Soc. 2020 Aug 26;0.
- Deng M, Qi Y, Deng L, Wang H, Xu Y, Li Z, et al. Obesity as a Potential Predictor of Disease Severity in Young COVID-19 Patients: A Retrospective Study. Obesity. 2020 Jun;0–3.
- Gao S, Jiang F, Jin W, Shi Y, Yang L, Xia Y, et al. Risk factors influencing the prognosis of elderly patients infected with COVID-19: a clinical retrospective study in Wuhan, China. Aging (Albany NY). 2020 Jan 1;12(13):12504–16.
- Gupta R, Agrawal R, Bukhari Z, Jabbar A, Wang D, Diks J, et al. Higher Comorbidities and Early Death is Characteristic of Hospitalized African-American Patients with COVID-19. medRxiv. 2020 Jan 1;2020.07.15.20154906.
- 35. Han M, Ma K, Wang X, Yan W, Wang H, You J, et al. Higher fasting plasma glucose reduced the survival rate of 306 hospitalized patients with COVID-19 in Wuhan, China. SSRN Electron J. 2020;
- 36. Huang R, Zhu L, Xue L, Liu L, Yan X, Wang J, et al. Clinical findings of patients with

coronavirus disease 2019 in Jiangsu province, China: A retrospective, multi-center study. PLoS Negl Trop Dis. 2020 May 8;14(5):e0008280–e0008280.

- Iacobellis G, Penaherrera CA, Bermudez LE, Bernal Mizrachi E. Admission hyperglycemia and radiological findings of SARS-CoV2 in patients with and without diabetes. Diabetes Res Clin Pract. 2020/05/01. 2020 Jun;164:108185.
- 38. Li Y, Han X, Alwalid O, Cui Y, Cao Y, Liu J, et al. Baseline characteristics and risk factors for short-term outcomes in 132 COVID-19 patients with diabetes in Wuhan China: A retrospective study. Diabetes Res Clin Pract. 2020 Aug 1;166.
- Liu S-P, Zhang Q, Wang W, Zhang M, Liu C, Xiao X, et al. Hyperglycemia is a strong predictor of poor prognosis in COVID-19. Diabetes Res Clin Pract. 2020 Jul 23;167:108338.
- Mejia-Vilet JM, Cordova-Sanchez BM, Fernandez-Camargo D, Mendez-Perez RA, Morales-Buenrostro LE, Hernandez-Gilsoul T. A Risk Score to Predict Admission to Intensive Care Unit in Patients With COVID-19: The ABC-GOALS Score. medRxiv. 2020 Jan 1;2020.05.12.20099416.
- Shi Q, Zhang X, Jiang F, Zhang X, Hu N, Bimu C, et al. Clinical Characteristics and Risk Factors for Mortality of COVID-19 Patients With Diabetes in Wuhan, China: A Two-Center, Retrospective Study. Diabetes Care. 2020 Jul;43(7):1382–91.
- 42. Smith SM, Boppana A, Traupman JA, Unson E, Maddock DA, Chao K, et al. Impaired glucose metabolism in patients with diabetes, prediabetes, and obesity is associated with severe COVID-19. J Med Virol. 2020 Jun 26;10.1002/jmv.26227.
- Tu Y, Yang P, Zhou Y, Wen X, Li Q, Zhou J, et al. Factors Associated with Early Invasive Ventilation in Critically III Patients with COVID-19: A Single-Centered, Retrospective, Observational Study. SSRN Electron J. 2020;
- 44. Wang F, Yang Y, Dong K, Yan Y, Zhang S, Ren H, et al. CLINICAL CHARACTERISTICS OF 28 PATIENTS WITH DIABETES AND COVID-19 IN WUHAN, CHINA. Endocr Pract Off J Am Coll Endocrinol Am Assoc Clin Endocrinol. 2020 Jun;26(6):668–74.
- 45. Wu C, Chen X, Cai Y, Xia J, Zhou X, Xu S, et al. Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China. JAMA Intern Med. 2020 Mar 13;180(7):1–11.
- 46. Wu J, Huang J, Zhu G, Wang Q, Lv Q, Huang Y, et al. Elevation of blood glucose level predicts worse outcomes in hospitalized patients with COVID-19: a retrospective cohort study. BMJ open diabetes Res care. 2020 Jun;8(1):e001476.

- Yan Y, Yang Y, Wang F, Ren H, Zhang S, Shi X, et al. Clinical characteristics and outcomes of patients with severe covid-19 with diabetes. BMJ Open Diabetes Res & amp; amp; Care. 2020 Apr 1;8(1):e001343.
- Yang J-K, Jin J-M, Liu S, Bai P, He W, Wu F, et al. Blood Glucose Is a Representative of the Clustered Indicators of Multi-Organ Injury for Predicting Mortality of COVID-19 in Wuhan, China. SSRN Electron J. 2020;
- Zhang J, Kong W, Xia P, Xu Y, Li L, Li Q, et al. Impaired Fasting Glucose and Diabetes Are Related to Higher Risks of Complications and Mortality Among Patients With Coronavirus Disease 2019. Front Endocrinol (Lausanne). 2020 Jul 10;11:525.
- Zhang Q, Wei Y, Chen M, Wan Q, Chen X. Clinical analysis of risk factors for severe COVID-19 patients with type 2 diabetes. J Diabetes Complications. 2020 Jun 29;107666.
- 51. Zhang Y, Li H, Zhang J, Cao Y, Zhao X, Yu N, et al. The clinical characteristics and outcomes of patients with diabetes and secondary hyperglycaemia with coronavirus disease 2019: A single-centre, retrospective, observational study in Wuhan. Diabetes Obes Metab. 2020/06/17. 2020 Aug;22(8):1443–54.
- 52. Zhou J, Tse G, Lee S, Liu T, Wu WKK, cao zhidong, et al. Identifying main and interaction effects of risk factors to predict intensive care admission in patients hospitalized with COVID-19: a retrospective cohort study in Hong Kong. medRxiv. 2020 Jan 1;2020.06.30.20143651.
- Zhu B, Jin S, Wu L, Hu C, Wang Z, Bu L, et al. J-shaped Association Between Fasting Blood Glucose Levels and COVID-19 Severity in Patients without Diabetes. Diabetes Res Clin Pract. 2020 Aug 24;108381.
- 54. Huguet A, Hayden JA, Stinson J, McGrath PJ, Chambers CT, Tougas ME, et al. Judging the quality of evidence in reviews of prognostic factor research: adapting the GRADE framework. Syst Rev. 2013 Sep 5;2:71.
- 55. Schünemann H, Brożek J, Guyatt G, Oxman A, editors. GRADE handbook for grading quality of evidence and strength of recommendations. Updated October 2013. The GRADE Working Group; 2013.